A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, and Daniel Thompson,(2) PharmD
From (1)Atrium Health, Levine Cancer Institute, Department of Pharmacy, Concord, North Carolina; (2)Atrium Health Cabarrus, Department of Pharmacy, Concord, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Donald C. Moore, PharmD, BCPS, BCOP, DPLA, Levine Cancer Institute,
100 Medical Park Drive, Concord, NC 28025.
J Adv Pract Oncol 2021;12(4):439–447 |
© 2021 Harborside™
The B-cell receptor signaling pathway plays an integral role in the proliferation and survival of malignant B cells. Targeting the B-cell receptor pathway via the inhibition of Bruton tyrosine kinase (BTK) has evolved the treatment of a variety of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia. Currently, there are three BTK inhibitors approved by the U.S. Food and Drug Administration: ibrutinib, acalabrutinib, and zanubrutinib. This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.
For access to the full length article, please sign in